Ads
related to: asthma management scholarly articles
Search results
Results From The WOW.Com Content Network
Bronchial thermoplasty [1] is a treatment for severe asthma approved by the FDA in 2010 involving the delivery of controlled, therapeutic radiofrequency energy to the airway wall, thus heating the tissue and reducing the amount of smooth muscle present in the airway wall.
The mechanisms behind allergic asthma—i.e., asthma resulting from an immune response to inhaled allergens—are the best understood of the causal factors. In both people with asthma and people who are free of the disease, inhaled allergens that find their way to the inner airways are ingested by a type of cell known as antigen-presenting ...
Reddell is a physician working in respiratory health, researching improved methods for treating asthma and respiratory conditions including COPD. [7] Her research focusses on improving the management, treatment and quality of life for people with respiratory conditions, including use of medicines in primary care, as well as monitoring populations and public health.
Current Allergy and Asthma Reports is a bimonthly peer-reviewed medical journal publishing review articles pertaining to allergy and asthma. It was established in 2001 and is published by Springer Science+Business Media. The editor-in-chief is David Peden (University of North Carolina at Chapel Hill School of Medicine).
In 2000-2001 asthma prevalence was monitored at 6.5%; by 2010-2011 a 4.3% increase was shown, with asthma prevalence totaling 10.8% of Canada's population. [29] Furthermore, asthma prevalence varies among the provinces of Canada; the highest prevalence is Ontario at 12.1%, and the lowest is Nunavut at 3.8%. [29]
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...